New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for...
Acurx Phamaceuticals
Biopharmaceutical -Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.
New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for...
Biopharmaceutical – Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.
From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for...
Biopharmaceutical – Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO
From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for...
Biopharmaceutical – Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet Follow New to the Street on Facebook:...